Literature DB >> 19412700

Intravitreal bevacizumab for CNV-complicated tilted disk syndrome.

Paolo Milani1, Alfredo Pece, Giuseppe Moretti, Pruneri Lino, Antonio Scialdone.   

Abstract

BACKGROUND: Tilted disc syndrome is a congenital anomaly characterized by an inferonasal "tilting" of the optic disc. We report three patients affected by macular neovascularisation-complicated tilted disk syndrome treated by intravitreal bevacizumab.
METHODS: Three interventional case reports are hereby documented. Ophthalmic evaluations were registered, including monthly visual acuity examination, OCT and fluorescein angiography before and after consecutive intravitreal injection of 1.25 mg bevacizumab (0.05 ml, Avastin).
RESULTS: All patients, aged more than 65 years, experienced decreased visual acuity after an observation period of 6 (two patients) and 3 months (one patient). Angiographic leakage with neuroretinal rarefaction and RPE/choriocapillary complex elevation at OCT remained persistent in two patients and reduced in one.
CONCLUSIONS: No benefit in terms of visual acuity was noted after intravitreal bevacizumab treatments. Larger studies should be conducted to confirm our small series observation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19412700     DOI: 10.1007/s00417-009-1096-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  12 in total

1.  Congenital tilted disk syndrome associated with parafoveal subretinal neovascularization.

Authors:  M Stur
Journal:  Am J Ophthalmol       Date:  1988-01-15       Impact factor: 5.258

2.  Choroidal neovascularization in tilted disc syndrome.

Authors:  M Prost; J J De Laey
Journal:  Int Ophthalmol       Date:  1988       Impact factor: 2.031

3.  The tilted disc.

Authors:  D Dorrell
Journal:  Br J Ophthalmol       Date:  1978-01       Impact factor: 4.638

4.  Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study.

Authors:  Alfredo Pece; Vincenzo Isola; Maria Vadalà; Domenica Matranga
Journal:  Retina       Date:  2006-09       Impact factor: 4.256

5.  Population prevalence of tilted optic disks and the relationship of this sign to refractive error.

Authors:  Jerry Vongphanit; Paul Mitchell; Jie J Wang
Journal:  Am J Ophthalmol       Date:  2002-05       Impact factor: 5.258

6.  Macular complications on the border of an inferior staphyloma associated with tilted disc syndrome.

Authors:  Hideo Nakanishi; Akitaka Tsujikawa; Norimoto Gotoh; Hisako Hayashi; Daisuke Iwama; Hiroshi Tamura; Atsushi Otani; Nagahisa Yoshimura
Journal:  Retina       Date:  2008 Nov-Dec       Impact factor: 4.256

7.  Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.

Authors:  Wai-Man Chan; Timothy Y Y Lai; David T L Liu; Dennis S C Lam
Journal:  Ophthalmology       Date:  2007-06-28       Impact factor: 12.079

8.  Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.

Authors:  Yasushi Ikuno; Kaori Sayanagi; Kaori Soga; Miki Sawa; Motokazu Tsujikawa; Fumi Gomi; Yasuo Tano
Journal:  Am J Ophthalmol       Date:  2008-09-06       Impact factor: 5.258

9.  Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.

Authors:  Magda Gharbiya; Francesca Allievi; Luigi Mazzeo; Corrado Balacco Gabrieli
Journal:  Am J Ophthalmol       Date:  2008-09-06       Impact factor: 5.258

Review 10.  Congenital anomalies of the optic disc.

Authors:  D J Apple; M F Rabb; P M Walsh
Journal:  Surv Ophthalmol       Date:  1982 Jul-Aug       Impact factor: 6.048

View more
  2 in total

1.  Analyses of shape of eyes and structure of optic nerves in eyes with tilted disc syndrome by swept-source optical coherence tomography and three-dimensional magnetic resonance imaging.

Authors:  K Shinohara; M Moriyama; N Shimada; N Nagaoka; T Ishibashi; T Tokoro; K Ohno-Matsui
Journal:  Eye (Lond)       Date:  2013-10-11       Impact factor: 3.775

2.  Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization.

Authors:  Paolo Milani; Amedeo Massacesi; Stefano Ciaccia; Marco Setaccioli; Stefania Moschini; Fulvio Bergamini
Journal:  Clin Ophthalmol       Date:  2012-11-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.